Compare Intuitive Surgical, Inc. (ISRG) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs JPMorgan Chase & Co — how do they compare? Intuitive Surgical, Inc. trades at $423.96 (market cap $146.76B), while JPMorgan Chase & Co trades at $332.99 (market cap $880.98B). The key difference: JPMorgan Chase & Co is far larger — about 6× Intuitive Surgical, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and JPMorgan Chase & Co for 127 Days on average.
| ISRG | JPM | |
|---|---|---|
Market Cap | $146.76B | $880.98B |
Volume | 2,529,814 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $592.85 | $365.18 |
52-Week Low | $332.02 | $282.84 |
Typical Hold Time | 84 Days | 127 Days |
Enterprise Value | $141.54B | $1.82T |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $415.41, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.80, and has shown consistent revenue growth, reaching $10.06B in 2025. Analyst consensus is strongly bullish with a $480.78 price target, though the stock faces headwinds from slower procedure growth in some markets.
The outlook for ISRG remains positive due to its dominant position in robotic surgery, expanding international presence, and high recurring revenue. Key risks include competitive pressures, regulatory hurdles, and economic sensitivity affecting procedure volumes. With solid fundamentals and analyst support, the stock offers growth potential, but investors should monitor execution against these risks.
JPMorgan Chase (JPM) trades at $331.42, up 0.56% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats but missed Q4 2025 expectations. Revenue grew to $181.85B in 2025 with solid profitability metrics including 33.38% net income margin and 18.43% ROE. Analyst consensus remains positive with 52.46% buy ratings and $373.18 price target representing 12.6% upside potential.
JPMorgan demonstrates fundamental strength with consistent revenue growth and industry-leading profitability, though negative cash flow trends and geopolitical risks warrant monitoring. The stock offers value at 14.2 P/E with institutional support, but investors should weigh macroeconomic uncertainties and banking sector volatility against the company's strong market position and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
